Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Trials

9 clinical trials for Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers — RECRUITING · NA
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors — RECRUITING · PHASE2
• Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer — RECRUITING · PHASE1
• Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer — RECRUITING · PHASE2
• Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer — COMPLETED · PHASE1
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer — COMPLETED · PHASE1

Refine this search